ABSTRACT:
Malignant cells multiplying unusually in the breast, ultimately increasing to the rest of the body if untreated. Breast cancer happens practically entirely in women. It is one of the leading causes of cancer related death, when it is the second most common cancer in women after lung, when it constitutes 23% of all cancer cases in women, moreover it presents the first in global mortality (18.6%) of cancer According to the latest statistics, breast cancer ranks the first number (2,088,849 new cases) of recorded cases worldwide, annually. Breast cancer is a significant and common disease that has a negative effect on women health, and deaths, 626,679 cases). Seventy four females have been included in the current study, they were classified into three groups depending on their health and the type of tumor suffered by patients. The first included 25 females with malignant breast tumors, the second group included 24 women who had benign breast tumors, and the last group included 25 women who appeared to be healthy. Sandwich-ELISA technique was followed for detecting of NSE concentration in the serum. Results showed a statistical significant increase of NSE concentration in the samples of malignant breast tumors as compared to those of benign breast tumors (p = 0.032). The highest levels of NSE were recorded in the samples of advanced malignancy stage (III), moreover; right breast injury had the highest proportion of cases recorded in the current study with higher levels of NSE compared to cases recorded in the left breast. Evaluation of the sensitivity% NSE showed a respectable proportion of the susceptibility of this enzyme (76 %) to the distinction between breast cancer patients and healthy individuals. Present work showed a gradual decrease in the levels of NSE after receiving the chemotherapy sequence. For the purpose of studying the possibility of using NSE as an effective tool in the follow-up response of breast cancer patients to treatment and evaluation of the healing stages on the one hand, on the other hand investigate the possibility of proliferation of cancer or recurrence, for that concentrations of NSE after receiving the last dosage of chemotherapy or (chemotherapy and radiotherapy) "according to the program suggested by the specialist" were compared with their levels in the group of patients with benign tumors and also with the control groups. Fifteen of the total patients (25 cases) who received chemotherapy (60% of all infected samples) showed significantly lower rates at the first diagnosis of the disease and this result enhances the possibility of using NSE as a tool to assess the extent of recovery of breast cancer patients.
Cite this article:
Rasha Hasan Jasim, Sara Abdalkareem Moshref. Neuron Specific Enolase: A New Marker for Diagnosis and Evaluating the Benefit of Specific Therapies in Treatment of Breast Cancer. Research J. Pharm. and Tech. 2020; 13(11):5365-5369. doi: 10.5958/0974-360X.2020.00938.5
Cite(Electronic):
Rasha Hasan Jasim, Sara Abdalkareem Moshref. Neuron Specific Enolase: A New Marker for Diagnosis and Evaluating the Benefit of Specific Therapies in Treatment of Breast Cancer. Research J. Pharm. and Tech. 2020; 13(11):5365-5369. doi: 10.5958/0974-360X.2020.00938.5 Available on: https://rjptonline.org/AbstractView.aspx?PID=2020-13-11-53
REFERENCES:
1. C. Breast, C. Be, F. Early, B. Ultrasound, E. Breast, and I. Tests, “Breast Cancer Early Detection and Diagnosis American Cancer Society Recommendations for the Early Detection of Breast Cancer,” pp. 1–60.
2. J. E. Lima, O. M. Takayanagui, L. V Garcia, and J. P. Leite, “Use of neuron-specific enolase for assessing the severity and outcome in patients with neurological disorders,” vol. 37, pp. 19–26, 2004.
3. A. E. B. C, A. F. Alfieri, I. T. Navarro, and G. L. A. Neuron-specific, “Neuron-specific enolase as biomarker for possible neuronal damage in dogs with distemper virus 1,” vol. 39, no. 1, pp. 47–51, 2019.
4. E. A. Konstantinou et al., “NSE ( NSE ): A Valuable Prognostic Factor of Central Nervous System Dysfunction Following Cardiac Surgery,” vol. 9, no. 1, pp. 22–28, 2008.
5. N. S. Matlab and R. H. Jasim, “Relationship of Serotonin to NSE In Serum Samples of Patients with Advanced Stages of Cancer Tumors,” Eur. Chem. Bull., vol. 6, no. 8, p. 350, 2017.
6. Q. Liu et al., “Distribution of serum neuron-specific enolase and the establishment of a population reference interval in healthy adults,” J. Clin. Lab. Anal., vol. 33, no. 5, 2019.
7. R. Polcyn, M. Capone, A. Hossain, D. Matzelle, N. L. Banik, and A. Haque, “NSE is a potential target for regulating neuronal cell survival and death : implications in neurodegeneration and regeneration,” pp. 4–7, 2017.
8. M. A. Isgrò, P. Bottoni, and R. Scatena, “Neuron-specifi c enolase as a biomarker: Biochemical and clinical aspects,” in Advances in Experimental Medicine and Biology, vol. 867, 2015, pp. 125–143.
9. M. Rundgren, T. Cronberg, H. Friberg, and A. Isaksson, “Serum NSE - Impact of storage and measuring method,” BMC Res. Notes, vol. 7, no. 1, 2014.
10. D. H. Johnson et al., “Potential Utility of Serum Neuron-specific Enolase Levels in Small Cell Carcinoma of the Lung1,” no. November, pp. 5409–5414, 1984.
11. N. Kamiya et al., “Pretreatment serum level of NSE (NSE) as a prognostic factor in metastatic prostate cancer patients treated with endocrine therapy,” Eur. Urol., vol. 44, no. 3, pp. 309–314, 2003.
12. P. B.I., S. M., T. D., S. T., A. S., and M. M., “NSE - Selective marker for small-cell lung cancer,” Radiology and Oncology, vol. 38, no. 1. p. 21, 2004.
13. E. Neuro-inflammation, “Brain sciences New Insights into the Role of Neuron-Specific,” 2018.
14. E. Baudin et al., “Neuron-specific enolase and chromogranin A as markers of neuroendocrine tumours,” vol. 78, pp. 1102–1107, 1998.
15. S. Wang, X. Zha, X. Zhu, W. Li, J. Ma, and Z. Wu, “Metabolic syndrome and its components with neuron-specific enolase : a cross- sectional study in large health check-up population in China,” pp. 1–8, 2018.
16. J. D. Middleton, D. G. Stover, and T. Hai, “Chemotherapy-Exacerbated Breast Cancer Metastasis: A Paradox Explainable by Dysregulated Adaptive-Response,” Int. J. Mol. Sci., vol. 19, no. 11, 2018.
17. E. Mercier et al., “Predictive value of neuron-specific enolase for prognosis in patients with moderate or severe traumatic brain injury: a systematic review and meta-analysis,” C. Open, vol. 4, no. 3, pp. E371–E382, 2016.
18. A. Martínez et al., “Cytosolic Fe-superoxide dismutase safeguards Trypanosoma cruzi from macrophage-derived superoxide radical,” Proc. Natl. Acad. Sci. U. S. A., vol. 116, no. 18, pp. 8879–8888, 2019.
19. F. E. E. De Vries, A. W. Walter, and B. C. Vrouenraets, “Intraductal papilloma of the male breast,” pp. 1–2, 2016.
20. M. Outcomes, “Association of Body Mass Index and Age With Subsequent Breast Cancer Risk in Premenopausal Women,” vol. 4, no. 11, pp. 1–10, 2018.
21. C. J. Nattenmüller et al., “Obesity as risk factor for subtypes of breast cancer : results from a prospective cohort study,” pp. 1–8, 2018.
22. J. A. Bonner et al., “Significance of Neuron-specific Enolase Levels before and during Therapy for Small Cell Lung Cancer 1,” vol. 6, no. February, pp. 597–601, 2000.
23. T. Vizin and J. Kos, “Gamma-enolase : a well-known tumour marker , with a less-known role in cancer Gamma-enolase,” pp. 217–226, 2015.
24. A. A. Knopp and A. Knopp, “A Comparison of Cyfra 21-1 , NSE , and CEA For the Serodiagnosis of Lung Cancer by,” 2015.
25. P. Johnsson et al., “Neuron-specific enolase increases in plasma during and immediately after extracorporeal circulation,” Ann. Thorac. Surg., vol. 69, no. 3, pp. 750–754, 2000.
26. J. E. Lima, O. M. Takayanagui, L. V. Garcia, and J. P. Leite, “Use of neuron-specific enolase for assessing the severity and outcome in patients with neurological disorders,” Brazilian J. Med. Biol. Res., vol. 37, no. 1, pp. 19–26, 2004.
27. A. Bharosay, V. Vikram, and R. Saxena, “Correlation of Brain Biomarker NSE ( NSE ) with Degree of Disability and Neurological Worsening in Cerebrovascular Stroke,” vol. 27, no. June, pp. 186–190, 2012.
28. F. Xue, L. Zhu, L. Wang, and Q. Wang, “Serum NSE levels correlate with patient prognosis for advanced lung cancer,” vol. 8, no. 6, pp. 9498–9504, 2015.
29. X. Liu et al., “The prognostic value of the serum NSE and lactate dehydrogenase in small cell lung cancer patients receiving fi rst-line platinum-based chemotherapy,” no. Ld.
30. W. Schoerkhuber et al., “Time Course of Serum Neuron-Specific Enolase,” Stroke, vol. 30, no. 8, pp. 1598–1603, 1999.